Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05476926 · ClinicalTrials.gov registry record

A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

A clinical trial of Diabetic Macular Edema and Neovascular Age-related Macular Degeneration, sponsored by Hoffmann-La Roche.

Active
Registry status
6,000
Enrollment target
20
Study locations

NCT05476926: Active study of Diabetic Macular Edema and Neovascular Age-related Macular Degeneration, sponsored by Hoffmann-La Roche.

NCT05476926 is a study of Diabetic Macular Edema and Neovascular Age-related Macular Degeneration that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 6,000 participants, above the 3,699-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (62% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05476926, a study of Diabetic Macular Edema and Neovascular Age-related Macular Degeneration, is active but no longer recruiting, sponsored by Hoffmann-La Roche.

ACTIVE NOT RECRUITING
Registry status
6,000 participants
Enrollment target
20
Study locations

Study Summary

The VOYAGER study is a primary data collection, non-interventional, prospective, multinational, multicenter study. It is designed to collect real-world, long-term data to explore long-term effectiveness, safety, clinical insights, treatment patterns, and factors driving the treatment decisions among patients being treated with specified Roche ophthalmology products in approved retinal indications (Faricimab for neovascular age-related macular degeneration \[nAMD\], diabetic macular edema \[DME\], and retinal vein occlusion; Port Delivery System with Ranibizumab for nAMD) in routine clinical practice. This study will not provide or make recommendations on use of any products including Roche products; treatment decisions will be determined by the treating physician and must be made independently to the decision to participate in this study. Participation in this study will not change or influence a patient's standard of care in any way.

Primary Outcome

Visual acuity will be collected as measured per local practice and then will be converted to the approximate ETDRS letter score.

Conditions Studied

Diabetic Macular Edema Neovascular Age-related Macular Degeneration Retinal Vein Occlusion Branch Retinal Vein Occlusion Central Retinal Vein Occlusion Hemi-retinal Vein Occlusion

Interventions

  • DRUG Faricimab
  • COMBINATION_PRODUCT Port Delivery System with Ranibizumab

Study Locations (20)

California

  • California Eye Specialists Medical group Inc. - Pasadena
  • Retinal Consultants Medical Group - Sacramento

Florida

  • Advanced Research - Coral Springs
  • Retina Specialty Institute - Pensacola

Illinois

  • University Retina and Macula Associates, PC - Lemont
  • Springfield Clinic, Llp - Springfield

Texas

  • Brown Retina Institute - San Antonio
  • Retina Center of Texas - Southlake

Virginia

  • Piedmont Eye Center - Lynchburg
  • Wagner Macula and Retina Center - Norfolk

Arizona

  • Retinal Research Institute, LLC - Phoenix

Kentucky

  • Retina Associates of Kentucky - Lexington

Maryland

  • Cumberland Valley Retina Consultants PC - Hagerstown

Trial Details

FieldValue
Enrollment Target 6,000 participants
Start Date 2022-11-21
Est. Completion 2027-11-30
Hoffmann-La Roche

909 total trials

What the registry record for NCT05476926 still lists

NCT05476926 is an observational study that tracks outcomes without assigning an intervention. Its 6,000 participants enrollment target places it among the larger protocols in the corpus, above the 3,699-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (62% higher).

The record links to 6 conditions, with Diabetic Macular Edema appearing as the primary indexed condition, and to 2 interventions - of which Faricimab is the first listed.

NCT05476926 names 20 study sites across 15 states, led by California, Florida, Illinois.

Frequently Asked Questions

What is clinical trial NCT05476926 about?

NCT05476926 is a clinical study titled "A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products". The VOYAGER study is a primary data collection, non-interventional, prospective, multinational, multicenter study. It is designed to collect real-world, long-term data to explore long-term effectiveness, safety, clinical insights, treatment patterns, and factors driving the treatment decisions among...

What is the current status of trial NCT05476926?

This trial is currently active not recruiting. The enrollment target is 6,000 participants. The study started on 2022-11-21. Estimated completion is 2027-11-30.

What conditions does trial NCT05476926 study?

This clinical trial studies the following conditions: Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusion, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion.

What interventions are being tested in trial NCT05476926?

The interventions under investigation include: Faricimab (DRUG), Port Delivery System with Ranibizumab (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT05476926?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05476926 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diabetic Macular Edema

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05476926's enrollment target sits among peer trials

6,000 2nd of 63 the highest of 63 other Diabetic Macular Edema trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetic Macular Edema trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00005095 · 6,000 participants

    Specimen and Data Study for Ovarian Cancer Early Detection and Prevention

  • NCT00280202 · 6,000 participants

    Detection of Genetic Markers of Lung Cancer

  • NCT03127631 · 6,000 participants · NA

    A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients

  • NCT03539705 · 6,000 participants

    Food Allergy Registry at a Single Site

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05476926, the US trial registry maintained by the National Library of Medicine. NCT05476926 (large enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.